JP2023550654A - 神経変性障害の治療のためのｃｙｐ４６ａ１阻害剤としての４－フルオロ－（４－（４－ベンジル）ピペリジン－１－イル）（２－（ピリミジン－４－イル）ピリジン－３－イル）メタノン誘導体および類似化合物 - Google Patents

神経変性障害の治療のためのｃｙｐ４６ａ１阻害剤としての４－フルオロ－（４－（４－ベンジル）ピペリジン－１－イル）（２－（ピリミジン－４－イル）ピリジン－３－イル）メタノン誘導体および類似化合物 Download PDF

Info

Publication number
JP2023550654A
JP2023550654A JP2023531565A JP2023531565A JP2023550654A JP 2023550654 A JP2023550654 A JP 2023550654A JP 2023531565 A JP2023531565 A JP 2023531565A JP 2023531565 A JP2023531565 A JP 2023531565A JP 2023550654 A JP2023550654 A JP 2023550654A
Authority
JP
Japan
Prior art keywords
compound according
compound
disorder
disease
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023531565A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023550654A5 (https=
Inventor
スティーブン ミシュク，
アレン テイラー ホッパー，
ダニエル ラ，
マリア－ヘスス ブランコ－ピヤド，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sage Therapeutics LLC
Original Assignee
Sage Therapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sage Therapeutics LLC filed Critical Sage Therapeutics LLC
Publication of JP2023550654A publication Critical patent/JP2023550654A/ja
Publication of JP2023550654A5 publication Critical patent/JP2023550654A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2023531565A 2020-11-25 2021-11-24 神経変性障害の治療のためのｃｙｐ４６ａ１阻害剤としての４－フルオロ－（４－（４－ベンジル）ピペリジン－１－イル）（２－（ピリミジン－４－イル）ピリジン－３－イル）メタノン誘導体および類似化合物 Pending JP2023550654A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063118291P 2020-11-25 2020-11-25
US63/118,291 2020-11-25
PCT/US2021/060844 WO2022115620A1 (en) 2020-11-25 2021-11-24 4-fluoro-(4-(4-benzyl)piperidin-1-yl)(2-(pyrimidin-4-yl)pyridin-3-yl)methanone derivatives and similar compounds as cyp46a1 inhibitors for the treatment of neurodegenerative disorders

Publications (2)

Publication Number Publication Date
JP2023550654A true JP2023550654A (ja) 2023-12-04
JP2023550654A5 JP2023550654A5 (https=) 2024-12-03

Family

ID=79021144

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023531565A Pending JP2023550654A (ja) 2020-11-25 2021-11-24 神経変性障害の治療のためのｃｙｐ４６ａ１阻害剤としての４－フルオロ－（４－（４－ベンジル）ピペリジン－１－イル）（２－（ピリミジン－４－イル）ピリジン－３－イル）メタノン誘導体および類似化合物

Country Status (6)

Country Link
US (1) US20230312522A1 (https=)
EP (1) EP4251618A1 (https=)
JP (1) JP2023550654A (https=)
CA (1) CA3203010A1 (https=)
IL (1) IL303170A (https=)
WO (1) WO2022115620A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL309208A (en) 2021-06-11 2024-02-01 Sage Therapeutics Inc Neuroactive steroid for the treatment of alzheimer's disease
CN115745766B (zh) * 2022-10-27 2024-05-14 兰州康鹏威耳化工有限公司 一种三氟苯甲醛及三氟苄溴的制备方法
CN117126076A (zh) * 2023-07-20 2023-11-28 清源创新实验室 一种2,4,6-三氟苯乙腈的制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013504613A (ja) * 2009-09-16 2013-02-07 ザ ユニバーシティ オブ エディンバラ （４−フェニル−ピペリジン−１−イル）−［５−（１ｈ−ピラゾール−４−イル）−チオフェン−３−イル］−メタノン化合物及びそれらの使用
JP2013527162A (ja) * 2010-04-29 2013-06-27 ザ ユニバーシティ オブ エディンバラ １１β−ＨＳＤ１の阻害剤としての３，３−二置換−（８−アザ−ビシクロ［３．２．１］オクタ−８−イル）−［５−（１Ｈ−ピラゾール−４−イル）−チオフェン−３−イル］−メタノン類

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5854204A (en) 1995-03-14 1998-12-29 Praecis Pharmaceuticals, Inc. Aβ peptides that modulate β-amyloid aggregation
JP2001500852A (ja) 1996-08-27 2001-01-23 プレーシス ファーマスーティカルズ インコーポレイテッド Ｄ―アミノ酸を含むβ―アミロイドペプチド凝集のモジュレーター
AP2014007606A0 (en) * 2011-10-07 2014-05-31 Takeda Pharmaceutical 1-Arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases
MX2022003845A (es) * 2019-09-30 2022-06-22 Actinogen Medical Ltd Tratamientos cognitivos medicinales.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013504613A (ja) * 2009-09-16 2013-02-07 ザ ユニバーシティ オブ エディンバラ （４−フェニル−ピペリジン−１−イル）−［５−（１ｈ−ピラゾール−４−イル）−チオフェン−３−イル］−メタノン化合物及びそれらの使用
JP2013527162A (ja) * 2010-04-29 2013-06-27 ザ ユニバーシティ オブ エディンバラ １１β−ＨＳＤ１の阻害剤としての３，３−二置換−（８−アザ−ビシクロ［３．２．１］オクタ−８−イル）−［５−（１Ｈ−ピラゾール−４−イル）−チオフェン−３−イル］−メタノン類

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BIOCHEMICAL PHARMACOLOGY, vol. 148, JPN6025038963, 2018, pages 88 - 99, ISSN: 0005690255 *
REGISTRY (STN) [ONLINE], JPN6025038962, 24 February 2019 (2019-02-24), ISSN: 0005690256 *
SCOTT P WEBSTER ET AL: "SELECTION AND EARLY CLINICAL EVALUATION OF THE BRAIN-PENETRANT 11[BETA]-HYDROXYSTEROID 以下備考", BRITISH JOURNAL OF PHARMACOLOGY, vol. VOL.174, NR.5, JPN5024006242, 25 January 2017 (2017-01-25), GB, pages 396 - 408, ISSN: 0005690254 *

Also Published As

Publication number Publication date
US20230312522A1 (en) 2023-10-05
IL303170A (en) 2023-07-01
WO2022115620A1 (en) 2022-06-02
CA3203010A1 (en) 2022-06-02
EP4251618A1 (en) 2023-10-04

Similar Documents

Publication Publication Date Title
JP7687964B2 (ja) 化合物、組成物、および使用方法
JP6388991B2 (ja) キナーゼ阻害剤としてのアミノヘテロアリールベンズアミド
KR101643426B1 (ko) 키나아제 억제제로서의 피롤로피리딘
JP2025504486A (ja) Ｋｒａｓの標的分解のための化合物及び方法
JP6360879B2 (ja) キナーゼ阻害剤としてのビアリールアミド化合物
EP3191478B1 (en) Compounds and compositions as raf kinase inhibitors
AU2017304761B2 (en) Pharmaceutical compounds
US20230312522A1 (en) Cyp46a1 inhibitors and methods of use thereof
TW202309039A (zh) 用於靶向布魯頓氏酪胺酸激酶降解之化合物
KR20140075692A (ko) C-kit 키나제 억제제로서의 화합물 및 조성물
AU2019267166A1 (en) Furin inhibitors
JP2023544789A (ja) Ｍｒｇｘ２アンタゴニスト
AU2016366546A1 (en) Inhibitors of bruton's tyrosine kinase and methods of their use
EP4284801A1 (en) Small molecule inhibitors of salt inducible kinases
KR20240038996A (ko) 코로나바이러스 관련 질환의 치료를 위한 화합물 및 조성물
US12559508B2 (en) Semi-saturated bicyclic derivatives and related uses
JP2026504952A (ja) Ｍｅｔｔｌ３阻害剤としてのピペリジン誘導体
JP2021525220A (ja) ４−ヒドロキシピペリジン誘導体およびユビキチン特異的プロテアーゼ１９（ｕｓｐ１９）の阻害剤としてのその使用
US20260015360A1 (en) Biaryl derivatives and related uses
EP3134406A1 (en) Substituted 2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole and 4,5,6,7-tetrahydro-2h-pyrazolo [4,3-c]pyridine compounds as glyt1 inhibitors
OA21863A (en) Indazole based compounds and associated methods of use.
WO2026024373A2 (en) Cdk2 inhibitors for the treatment of cancer
CN121712766A (zh) 吗啉促食欲素受体拮抗剂
HK40082879A (zh) 杂环化合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241125

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241125

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250918

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250925

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251211

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260218

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260313